Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å undersøke sikkerheten og toleransen til intravenøs QEQ278 hos pasienter med avanserte solide svulster

9. november 2026 oppdatert av: Novartis Pharmaceuticals

En fase I/Ib, åpen etikett, multisenterstudie av QEQ278 hos pasienter med avanserte solide svulster

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.

Studieoversikt

Detaljert beskrivelse

This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.

In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.

The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.

Studietype

Intervensjonell

Registrering (Faktiske)

30

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Brussels, Belgia, 1200
        • Novartis Investigative Site
    • California
      • Los Angeles, California, Forente stater, 90095
        • University of California LA
    • Florida
      • Fort Myers, Florida, Forente stater, 33901
        • Florida Cancer Specialists
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital Dept. of Mass General Hospital
      • Paris, Frankrike, 75231
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italia, 20133
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Japan, 2778577
        • Novartis Investigative Site
      • Singapore, Singapore, 168583
        • Novartis Investigative Site
      • Barcelona, Spania, 08035
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Novartis Investigative Site
      • Essen, Tyskland, 45147
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Signed informed consent must be obtained prior to participation in the study.
  • Adult men and women ≥ 18 years of age.
  • Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
  • In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
  • Non-small cell lung cancer
  • Esophageal squamous cell carcinoma
  • Renal cell carcinoma
  • HPV-associated head and neck squamous cell carcinoma
  • Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.

Exclusion Criteria:

  • Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
  • Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
  • Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
  • Clinically significant cardiac disease or risk factors at screening
  • Insufficient bone marrow function at screening:
  • Infections:
  • Known history of testing positive for Human Immunodeficiency Virus infection.
  • Active Hepatitis B and / or Hepatitis C.
  • Active, documented COVID-19 infection
  • Known history of tuberculosis
  • Any serious uncontrolled infection (acute or chronic).
  • Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.

Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part 1: Dose escalation

Dose escalation with QEQ278 single agent

Intravenous dosing of QEQ278

Eksperimentell: Part 2: Dose expansion

Dose expansion with QEQ278 single agent

Intravenous dosing of QEQ278

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278
Tidsramme: 28 days

A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT evaluation period and meets the criteria defined in the study protocol.

28 days
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: Up to 31 months

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, and electrocardiograms (ECGs) qualifying and reported as AEs.

Up to 31 months
Frequency of dose interruptions, reductions
Tidsramme: Up to 30 months

Number of dose interruptions of QEQ278 and number of dose reductions of QEQ278

Up to 30 months
Dose intensity
Tidsramme: Up to 30 months

Dose intensity of QEQ278 is defined as the ratio of actual cumulative dose received and actual duration of exposure.

Up to 30 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall response rate (ORR) per RECIST v1.1
Tidsramme: Up to 30 months

ORR is defined as the proportion of patients with a confirmed BOR of complete response (CR) or partial response (PR) by local investigator review as per RECIST v1.1.

Up to 30 months
Disease control rate (DCR) per RECIST v1.1
Tidsramme: Up to 30 months

DCR is defined as the proportion of patients with a confirmed best overall response (BOR) of CR or PR or stable disease (SD) by local investigator review as per RECIST v1.1.

Up to 30 months
Duration of Response (DOR) per RECIST v1.1
Tidsramme: Up to 30 months

DOR is defined as the time form the date of the first documented response (CR or PR) to the date of the first documented progression by local investigator review as per RECIST v1.1 or death due to underlying cancer.

Up to 30 months
Progression-free survival (PFS) per RECIST v 1.1
Tidsramme: Up to 30 months

PFS is defined as the time from the date of start of treatment to the date of the first documented progression by local investigator review as per RECIST v1.1, or death due to any cause.

Up to 30 months
Peak serum concentration (Cmax) of QEQ278
Tidsramme: During first 168 days of treatment

The maximum (peak) serum drug concentration after single dose administration

During first 168 days of treatment
Area under the concentration time curve (AUC) last of QEQ278
Tidsramme: During first 168 days of treatment

The AUC from time zero to the last measurable concentration sampling time

During first 168 days of treatment
Area under the concentration time curve (AUC) infinity of QEQ278
Tidsramme: During first 168 days of treatment

The AUC from time zero to infinity

During first 168 days of treatment
Time to reach peak serum concentration (Tmax) of QEQ278
Tidsramme: During first 168 days of treatment

The time to reach maximum (peak) serum drug concentration after single dose administration

During first 168 days of treatment
Elimination half-life (T1/2) of QEQ278
Tidsramme: During first 168 days of treatment

The elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve

During first 168 days of treatment
Total body clearance (CL) of QEQ278
Tidsramme: During first 168 days of treatment

The total body clearance of drug from the serum

During first 168 days of treatment
Volume of distribution (Vz) of QEQ278
Tidsramme: During first 168 days of treatment

The apparent volume of distribution during terminal phase

During first 168 days of treatment
Incidence of anti-drug antibody (ADA)
Tidsramme: Day 1 and 15

Immunogenicity of QEQ278

Day 1 and 15

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. april 2023

Primær fullføring (Faktiske)

26. januar 2026

Studiet fullført (Faktiske)

26. januar 2026

Datoer for studieregistrering

Først innsendt

14. juli 2022

Først innsendt som oppfylte QC-kriteriene

14. juli 2022

Først lagt ut (Faktiske)

18. juli 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. februar 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere